Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
20.8(c) 19.54(c) 19.68(c) 26.25(c) 27.27(c) Last
147 961 313 569 232 030 9 203 715 1 528 986 Volume
+2.67% -6.06% +0.72% +33.38% +3.89% Change
More quotes
Financials ($)
Sales 2017 3,36 M
EBIT 2017 -110 M
Net income 2017 -113 M
Debt 2017 -
Yield 2017 -
Sales 2018 58,5 M
EBIT 2018 -83,8 M
Net income 2018 -84,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 258x
Capi. / Sales2018 14,8x
Capitalization 865 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies.It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis.Its products include Zilretta.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
03/24 WHAT MIGHT SANOFI SA (ADR) (NYSE : SNY) Mean For Flexion Therapeutics (NASDAQ:FL..
03/24 FLEXION THERAPEUTICS : Burlington biotech Flexion could be sold to Sanofi
03/10 FLEXION THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
03/10 FLEXION THERAPEUTICS : Reports Year-End 2016 Financial Results
03/09 FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition, Change..
03/09 Flexion Reports Year-End 2016 Financial Results
03/03 Flexion Therapeutics to Present at Upcoming Investor Conferences
03/02 Flexion Therapeutics to Report Year-End 2016 Financial Results on March 9, 20..
02/23 Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repea..
02/15 Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare ..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/25$FLXN - Flexion Therapeutics Inc #FLXN Earns "Overweight" Rating from Cantor .. 
03/25Flexion Therapeutics's overweight rating reiterated at Cantor Fitzgerald. $34.. 
03/25Flexion Therapeutics's outperform rating reiterated at Wells Fargo & Co. .. 
03/24Biotech Forum Daily Digest: Obamacare To Stay? Flexion On The Block? Spotligh.. 
03/24#DownSideMomentum $FLXN FLEXION THERAPEUTICS #TradeIdeas via ?  
More tweets
Qtime:13
News from SeekingAlpha
03/24 BIOTECH FORUM DAILY DIGEST : Obamacare To Stay? Flexion On The Block? Spotlight ..
03/23 Midday Gainers / Losers
03/23 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
03/23 Flexion spikes 26% on pending Sanofi takeover
03/09 Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q4 2016 Results - Earnings C..
Advertisement
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Full-screen chart
Technical analysis trends FLEXION THERAPEUT...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 35,4 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer & Director
Patrick J. Mahaffy Chairman
Dan Leblanc Senior Vice President-CMC Operations
Frederick W. Driscoll Chief Financial Officer
Neil Bodick Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS I..43.38%865
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results